21 August 2025 11:28
Topic starter
2
Do you really need a psychotherapist for psychedelics therapy?
4 Answers
2
21 August 2025 17:09
You have for a psychedelic session not necessarily need a psychotherapist. Which coach suits you best depends on your goal and personal preference.
Under current legislation in the Netherlands, the following applies: psychedelic therapy is not a recognized medical treatment. This means that psychologists, psychosocial therapists, and experienced counselors may be involved, but that, strictly speaking, it is alternative or complementary guidance. An official psychotherapist (with BIG registration) may only use the title "psychotherapist" in a recognized medical context. Psychedelic psychotherapy is currently not yet officially permitted, because psilocybin and MDMA are still in the research phase as medicines. However, there are practitioners with a psychological or therapeutic background who perform this work legally, provided they work with legal substances such as truffles (more explanation about psychedelic therapy).
Many clients notice that the quality of guidance is more important than the title. Some consciously choose a psychologist or psychosocial therapist because they desire therapeutic depth and are looking for someone with experience in trauma, depression, or anxiety. Others feel more comfortable with a peer support worker or spiritual guide, as the emphasis lies less on cognitive interventions and more on surrender and experience.
This is also reflected on the forum: participants indicate that the presence of a psychologist helped them with integration and processing, but others found the gentler, intuitive guidance of a tripsitter sufficient. It is important that you know that safety, experience and integration guidance form the core, and not so much the official title of the supervisor (forum discussion on qualifications and guidance).
In short: a psychotherapist is not mandatory. You can choose a facilitator whose style and background best suit your intentions. If you primarily want to work therapeutically in depth with, for example, trauma or PTSD, then a psychologist or therapist such as Sascha, Reineke, or Ronald might be suitable. If you want more spiritual or personal growth without an emphasis on forms of therapy, then an experienced tripsitter can also be an excellent choice.
2
21 August 2025 17:14
Practical experience and scientific insights show that a large part of the healing effect of psychedelics does not stem so much from talk therapy, but rather from the biological and internal processes the substance itself sets in motion. Substances such as psilocybin and LSD increase BDNF (a growth factor that stimulates new brain connections), activate the mTOR pathway for cell repair, reduce neuroinflammation, and even contribute to cell rejuvenation, among other things. These effects occur independently of a psychotherapeutic session and ensure that the brain literally becomes more flexible and can let go of old patterns. As a result, many people experience breakthroughs and emotional release without the need for in-depth psychotherapy.
That does not mean that guidance is superfluous. The difference often lies in the form of guidance. Some people feel most comfortable with an experienced tripsitter or guide, who ensures safety and provides the space for a deep journey. Others prefer a psychologist or therapist, especially if there is complex trauma or a history of severe psychological issues. Experience shows that approximately 60% of the participants benefit most from guidance by an expert without this necessarily having to be formal psychotherapy, while only about 10% benefit from a full psychotherapeutic framework.
Participants on the forum also share that a session with an experienced guide without a psychological background sometimes resonates better than a session with a psychologist. Psychologists are often more focused on the cognitive side, whereas a tripsitter can facilitate the magical, emotional, or spiritual dimension of a truffle ceremony or psilocybin session. For many people, that is precisely where the transformative power of the experience lies.
In short: psychedelic therapy does not always have to be accompanied by psychotherapy. For many people, the biochemical and spiritual effects of psychedelics are healing in themselves, provided there is a safe setting and expert guidance. A psychotherapeutic approach can be valuable only in cases of complex backgrounds or severe trauma.
1
22 August 2025 11:18
It really also depends on whether you are doing hallucinogenic drug therapy or something like MDMA therapy. With MDMA therapy, it is more about the conversations and talk therapy than when you do a truffle cure or ayahuasca, which is more about the effects of the drug itself. And the goal is different for each person as well. But I also think that for all psychedelic sessions combined, a psychotherapist is actually not practical for a large group, whereas for a smaller group it is.
0
21 August 2025 11:58
No, A psychotherapist is not necessarily required. to achieve the therapeutic effect of psychedelics. There is solid evidence that certain substances also without guided psychotherapy can produce clinically relevant effects. At the same time, the following applies: complex mental disorders good guidance by a psychotherapist or psychedelics expert (psychoeducation, preparation, integration) usually increases the safety, effect size and sustainability. So the answer is: It can be done without, but It is not always wise to do it without (experienced) guidance—and for some indications, more intensive psychotherapy is indeed recommended.
Studies on psychedelics without psychotherapy:
Psychedelics are usually studied in combination with supervised psychotherapy, but there are also indications that these substances can have therapeutic effects on their own. Below, we have collected scientific studies (clinical, preclinical, and observational) that show that psilocybin, LSD, ayahuasca, MDMA and related analogues (such as methylone) can have a therapeutic effect without that a psychotherapist is involved. For each study, we state the substance, the application/condition, the study type, the nature of the intervention (without psychotherapy), the main findings, and any methodological remarks.
| Substance | Condition / Application | Study type (year, n) | Intervention (without psychotherapy) | Key findings | Methodological remarks |
|---|---|---|---|---|---|
| Psilocybin & LSD | Cluster headache (episodic and chronic) | Observational study (2006, n=53) | Self-treatment by patients with psilocybin or LSD, without therapeutic supervision. | 22 out of 26 users reported that psilocybin triggered an acute cluster headache attack. stopped. Additionally, 25 of 48 psilocybin users and 7 of 8 LSD users reported that their entire cluster period was terminated prematurely. Also, 18 of 19 psilocybin users and 4 of 5 LSD users indicated that the remission time between attacks was prolonged. | Observation and self-reporting; no control group. Possible selection bias (enthusiastic users). Nevertheless, it points to a direct physiological effect of psychedelics on cluster headache. |
| Psilocybin | Microdosing for well-being (various mental functions) | Prospective observation (2019, n=98) | Regularly microdosing (very low doses) by users, without therapy or supervision. | On days that participants microdosed, they reported a improvement in their psychological functioning (including mood, attention, productivity) compared to non-dosing days. Over six weeks, reported depression and stress decreased slightly on average af, and the ability to concentrate increased. However, no lasting effects were found after the dosing days, and certain personality aspects (such as neuroticism) actually increased. | No placebo or control group; expectation effects likely play a role. Results suggest slight benefits, but causality is uncertain. Later placebo-controlled research found hardly any difference compared to placebo (pointing to strong placebo effects). |
| LSD | Pain relief (experimental pain stimulus) | Double-blind placebo-controlled (2021, n=24) | Low dose LSD (5–20 µg, subhallucinogenic) in healthy volunteers, without psychological intervention. | A single low dose of LSD of 20 µg resulted in a significant Analgesic effect: participants could tolerate ice-cold water longer and reported less pain and discomfort. This analgesic effect lasted for hours, while the psychedelic effects were minimal. | Robust RCT with placebo; small sample but crossover design. Demonstrates that LSD itself can provide physiological analgesia without therapy. Further studies in patients with chronic pain are needed (promising but not yet clinically tested). |
| Ayahuasca | Depression (treatment-resistant depression) | Open-label clinical trial (2015, n=6) | One oral dose ayahuasca administered in a psychiatric ward, without additional psychotherapy (only medical monitoring). | A fast and strong decrease in depression scores (HAM-D and MADRS): ~82% symptom reduction within 1 day, effect persistent after 7 and 21 days. Additionally, anxious-depressive symptoms decreased significantly. No signs of mania or psychosis occurred after the dose, suggesting that intense psychedelic experiences not necessary are for mood improvement. | Very small study without a control group. Results are impressive but preliminary. The lack of a placebo arm means that expectations cannot be ruled out. However, it is an important first indication of a direct antidepressant effect of ayahuasca. |
| Ayahuasca | Depression (treatment-resistant depression) | Double-blind RCT (2018, n=29) | One dose of ayahuasca vs. placebo in a hospital setting, without psychotherapy (a safe setting with medical supervision). | Significant better antidepressant response with ayahuasca than with placebo. 1 day After ingestion, depression scores (MADRS) were lower in the ayahuasca group, and this difference widened on day 2 and day 7. After 7 days, ~64% of the ayahuasca patients had a clinical response (vs. 27% in the placebo group; p = 0.04). Effect sizes increased to a large magnitude (Cohen's d ~1.5 on day 7). | First placebo-controlled study with a psychedelic agent for depression. Strong design (randomized, double-blind). Limited by small sample size and short follow-up (1 week). No therapy added, so the effect is likely due to the pharmacological and introspective effects of ayahuasca itself. |
| MDMA | Depression (preclinical model) | Animal study (2011, rat model) | Acute MDMA administration for “depressed” rats (Flinders Sensitive Line) before behavioral test; naturally, no psychotherapy for animals. | A a few MDMA dose resulted in a dose-dependent antidepressant-like Effect: “Depressed” rats became much less immobile in the forced-swim test compared to untreated rats. The effect was strongest at the higher dose (10 mg/kg), comparable to classic antidepressants. Repeated administration reduced this effect again, indicating the development of tolerance. | Preclinical evidence suggests that MDMA itself (without therapy) can induce acute mood improvement. Its relevance to humans is indirect, but it supports the idea that MDMA plays a pharmacological role in depression. |
| MDMA | Anxiety disorder / PTSD model (fear extinction) | Animal study (2015, mice) | MDMA injection given before extinction training (exposure to fear-inducing stimulus) in mice; not therapy, only a learning procedure. | MDMA (7.8 mg/kg) before the session improved strongly and long-lasting the extinction of fear memories. Mice given MDMA showed much less freezing (fear response) during and days after extinction training compared to control mice. The MDMA treatment also increased markers of neuronal activity and neurotrophin (BDNF) in the amygdala and prefrontal cortex, pointing to a biological mechanism behind the improved fear extinction. This suggests that MDMA directly facilitates the learning process of fear reduction. | Highly controlled animal research that provides a mechanistic basis for MDMA's effect. It emphasizes that MDMA yourself makes the brain more sensitive to fear processing. In clinical practice, MDMA is always given with therapy for PTSD, but these data show that the pharmacological component makes a crucial contribution to the therapeutic effect. |
| Methylone (MDMA analog) | Depression & anxiety (preclinical) | Animal study (2023, rats) | Methylone-administration to rats, followed by behavioral tests (swimming test for depression, open field for anxiety). No psychological intervention. | A single dose methylone caused a fast and powerful Antidepressant response in the rats: immobility in the swim test decreased by ~95% compared to control animals. This effect lasted at least 72 hours after a single dose. By comparison, three doses of an SSRI (fluoxetine) resulted in a reduction of only ~50% for <24 hours. Furthermore, methylone showed anxiolytic inhibition: treated rats explored the open field more (spent more time in the center) than controls. | Very positive preclinical result, indicating potential fast Antidepressant effect. Supported by initial clinical observations (case series) in PTSD and depression patients. Note: this study was conducted by parties involved in a pharmaceutical program (potential conflict of interest). Clinical validation in larger studies is still lacking. |
| Methylone | PTSD (Post-traumatic stress disorder) | Retrospective case series (2022, n=?), follow-up study | Psychiatric patients with PTSD received (outside of study) methylone as treatment, without structured therapy; symptoms were followed over time. | In this series of clinical case reports (number of patients not explicitly stated), it was reported that the addition of methylone led to symptom improvement in PTSD-patients. In long-term follow-up, PTSD symptoms remained alleviated in most, suggesting that methylone may be a lasting therapeutic effect can have. It was also noted that methylone was well tolerated and produced milder effects compared to MDMA. | Early clinical evidence based on cases, without a control group. Possible bias due to small sample size and no randomization. Nevertheless, significant because it provides direct human indications of efficacy without intensive psychotherapy. These data contributed to approval for further trials. |
What does the research show without psychotherapy?
There are multiple examples in which the fabric itself works therapeutically, with at most medical monitoring or basic support—but without structured psychotherapy.
-
Ayahuasca for depression. In a randomized, double-blind, placebo-controlled trial, led one dose of ayahuasca in a hospital setting (without a course of talk therapy) until rapid and clinically meaningful decreases in depression scores vs. placebo; the difference was already visible after 1–2 days and greater after 7 days. This points to an intrinsic antidepressant effect of the substance in a safe, but non-psychotherapeutic setting.
-
LSD and pain. In healthy volunteers, a low (sub-hallucinogenic) dose of LSD An measurable analgesic effect (higher pain tolerance, less pain perception) without any psychological intervention. This supports the idea that LSD can modulate pain via neurobiological mechanisms, independent of therapy.
-
Psilocybin/LSD and cluster headache. In a (classic) patient survey, many users reported that a dose psilocybin or LSD to attack aborted, cluster periods shortened and remissions extended, without psychotherapy. Despite limitations of self-reporting, this is consistent with a direct physiological effect
-
Microdosing and expectations. Prospective and placebo-controlled citizen science shows that microdosing sometimes daily well-being scores increases, but that placebo can explain a large part of that profit. This nuances claims about microdosing without therapy.
-
MDMA: mechanistic indications. In mouse models facilitates MDMA extinguishing fear via BDNF-dependent plasticity in the amygdala/prefrontal cortex—a direct neurobiological effect that is already visible without “talking” therapy. Clinically, MDMA is usually administered *with* therapy, but this animal work shows that the pharmacology itself can reinforce therapeutic learning curves.
When is more intensive psychotherapy advisable?
At PTSD, severe or chronic depression, complex comorbidity, trauma dynamics, addiction or when there safety risks play (e.g. suicidality, psychosis susceptibility), is a therapeutic framework Highly recommended. Psychotherapy helps to the experience frame, integrate and anchor in behavior—and reduces the risk that difficult emotions remain unlearned. Also practical: most modern psilocybin and MDMA trials are designed this way (with preparation and integration) because this safety and reproducibility increases.
Do you really need a psychotherapist for psychedelic therapy?
Current scientific insights show that psychedelics independent can have therapeutic effects, even without formal psychotherapy. Studies with ayahuasca for depression, LSD for pain, and psilocybin or LSD for cluster headaches show that the substances alone can bring about powerful changes. However, this does not mean that everyone can do it safely and effectively entirely on their own.
There is, in fact, a spectrum of support needs. On the one hand, there are people for whom the substance itself is sufficient, while others benefit from a therapeutic framework or are even completely unsuitable.
The middle route
Between full psychotherapy and being completely alone, there is a practical middle ground. This consists of:
-
Check medical screening and contraindications (for example, heart problems, susceptibility to psychosis).
-
Optimize set & setting, so that the environment is safe and supportive.
-
An experienced guide or tripsitter (not necessarily a psychotherapist) who can monitor safety, dosage, and process.
-
Post-integration check-ins, for example in the form of coaching, psycho-education, or reflective assignments, so that insights can find their place.
This model aligns closely with most studies in which psychotherapy was not necessarily applied, but a safe setting and monitoring were present.
Distribution in practice
Based on experience and estimation, you can roughly divide the population as follows:
- 25% a psychedelic session can be safe and effective for completely only undergo. This is depending on the dosage And the higher the dosage and effects, the sooner supervision is desirable.
- 60% has much benefit with the support of a psychedelics expert, such as an experienced tripsitter, trip therapist, or psychologist, but does not need to be a psychotherapist.
- 10% does have a fully psychotherapeutic framework necessary to work safely and constructively with psychedelics.
- 5% is not suitable for psychedelic sessions due to medical, psychiatric, or personal contraindications.
Conclusion
A psychotherapist is therefore not always necessary in psychedelic therapy. For the majority of people, guidance from an expert by experience or trip coach is sufficient. Only a small group requires intensive psychotherapy, while a quarter of people can even manage entirely without guidance. The key lies in a good screening and adjusting the level of guidance to the individual needs and safety.